Wisdom CSO, Inc.

Brian Drzyzga briandrzyzga@wisdomcso.com

Brian has extensive executive management experience in the pharmaceutical industry in areas such as: commercial operations, technology development and delivery, clinical trials management processes and systems. Brian’s commercial experience originated with Dendrite International, and has developed into directly managing commercial operations for Pliva, and Odyssey Pharmaceuticals.

He has held several senior positions in the areas of Product Innovation (R&D and Commercial software), Product Management, FDA Compliance (PDMA/Sample Management), Global Deployments, Marketing Support, Call Center Management, Account Management, P&L Management, e-Training, Alliance Management, Vendor Management, Logistics Management, M&A Evaluation (technical evals) and Sales Leadership.

Susan Budd susanbudd@wisdomcso.com

Susan has 15 years of domestic and SE Asia sales management and business development experience in various healthcare fields including pharma, biotech, managed care, and medical capital equipment sales. Susan was responsible for building a successful SE Asia Sales and Marketing Team for a Capital Equipment Company in Xiamen, China.

Steven Goldszak stevegoldszak@wisdomcso.com

Steve has over 20 years of pharmaceutical sales and management experience. Current accomplishments include creating customized sales teams and revenue producing solutions through the keen development and mentoring of individual sales representatives. Steve’s specialties also include individualized attention to sales forces and their related initiatives, such as; sales analytics, recruiting, professional coaching, training, Government Affairs, HR partnering, and Canadian Sales and Marketing.  Another notable achievement is Steve’s progression to Executive VP of Franchise Marketing and Sales with financial statement responsibilities that met and exceeded objectives each year.

During his time as Executive VP at Dupont Pharma, Steve had responsibility for the marketing and sales for Coumadin, "THE" leading anti-coagulant, both prior to and after the entry of generic competition. Through a variety of innovative initiatives focused upon large group practice/patient management, and an extraordinary Dispense as Written (DAW) campaign, Coumadin promotion grew the market, while maintaining outstanding share. Performance strongly exceeded forecasts, and The DAW rate of 42% was reported by IMS as the highest rate attained to date.